SODIUM PHENYLACETATE AND SODIUM BENZOATE

Post-LOE

sodium phenylacetate and sodium benzoate

MAIA Biotechnology

ANDAINTRAVENOUSSOLUTION

Approved

May 2017

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

2/8 — Basic

SODIUM PHENYLACETATE AND SODIUM BENZOATE (sodium phenylacetate and sodium benzoate) by MAIA Biotechnology is enzymes: n -acetylglutamate synthetase (nags), carbamyl phosphate synthetase (cps), argininosuccinate synthetase (ass), ornithine transcarbamylase (otc), argininosuccinate lyase (asl), or arginase (arg). First approved in 2017.

Drug data last refreshed 18h ago

Mechanism of Action

enzymes: N -acetylglutamate synthetase (NAGS), carbamyl phosphate synthetase (CPS), argininosuccinate synthetase (ASS), ornithine transcarbamylase (OTC), argininosuccinate lyase (ASL), or arginase (ARG). Sodium phenylacetate and sodium benzoate are metabolically active compounds that can serve as…

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Worked on SODIUM PHENYLACETATE AND SODIUM BENZOATE at MAIA Biotechnology? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.